TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6389273

Group type: EXPERIMENTAL
Intervention: Antacid group A (7.5 ml, 103.5 mmol antacid/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Antacid group B (15 ml, 207 mmol antacid/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Antacid group C (30 ml, 414 mmol antacid/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo group (15 ml)
Number of subjects: 107
Study: 31697724

Group type: EXPERIMENTAL
Intervention: GP care (WHO mhGAP training)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Clinical Psychologists care (co-location framework)
Number of subjects: 294
Study: 29661516

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 25443420

Group type: EXPERIMENTAL
Intervention: Standardized skin care regimen 1
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Standardized skin care regimen 2
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 23380429

Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam orodispersible tablet (ODT)
Number of subjects: 28
Study: 21512162

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1817
Study: 19477503

Group type: EXPERIMENTAL
Intervention: Thigh-length graduated compression stockings (GCS)
Number of subjects: 2518

Group type: COMPARATOR
Intervention: Avoidance of graduated compression stockings (GCS)
Number of subjects: 2518
Study: 17715080

Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous needle aspiration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 15208492

Group type: EXPERIMENTAL
Intervention: Dual-isotope gated myocardial perfusion SPECT (GMPS) with 201Tl injected at rest and 99mTc sestamibi (99mTc-MIBI) injected at peak stress
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Dual-isotope gated myocardial perfusion SPECT (GMPS)
Number of subjects: 236
Study: 11433048

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SNIPPV (in infants with poor lung function)
Number of subjects: 64

Group type: COMPARATOR
Intervention: NCPAP (in infants with poor lung function)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SNIPPV
Number of subjects: 64
Study: 8448744

Group type: EXPERIMENTAL
Intervention: Adjuvant recombinant IFN‐alpha‐2a (rIFN‐alpha 2a) (9 x 10(6) IU subcutaneously, three times per week for a maximum of 12 months)
Number of subjects: 270

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 270
Study: 3777684

Group type: EXPERIMENTAL
Intervention: Colloidal fluid loading (Group I, n = 20)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Blood transfusion (Group II, n = 17)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Catecholamine infusion (dopamine or dobutamine, Group III, n = 17)
Number of subjects: 54
Study: 29626145

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 306

Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 306
Study: 26925704

Group type: EXPERIMENTAL
Intervention: Sativex (up to 108 mg THC/100 mg CBD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sativex or placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Self-titrated doses of Sativex
Number of subjects: 9
Study: 24373290

Group type: EXPERIMENTAL
Intervention: Hand washing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control households
Number of subjects: 0
Study: 24077196

Group type: EXPERIMENTAL
Intervention: Lateral parasagittal interlaminar epidural steroid injection (PIL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Midline interlaminar epidural steroid injection (MIL)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Concordant pressure paresthesia during LESI
Number of subjects: 106
Study: 20509997

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg once daily for 48 weeks)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Adefovir (10 mg once daily for 48 weeks)
Number of subjects: 125
Study: 18204337

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 99
Study: 16131645

Group type: EXPERIMENTAL
Intervention: Male-to-female transgender persons who are HIV positive
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nontransgender control subjects who are HIV positive
Number of subjects: 59
Study: 12682421

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (400 IU dL-a-tocopherol daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study: 10750771

Group type: EXPERIMENTAL
Intervention: Cardiotomy suction during CPB to cardiotomy reservoir (CR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cell saving device (CS) during CPB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cell saving device (CS) reservoir
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood from the wound
Number of subjects: 20
Study: 9010746

Group type: EXPERIMENTAL
Intervention: Estradiol-releasing vaginal ring (2 mg/3 months) and oral progestin for 7 days every month
Number of subjects: 56

Group type: COMPARATOR
Intervention: Transdermal estrogen (50 micrograms/day) with a levonorgestrel-releasing IUD (20 micrograms/day)
Number of subjects: 56
Study: 1446959

Group type: EXPERIMENTAL
Intervention: Timonil 600 retard from Desitin Arzneimittel GmbH
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference preparation (R)
Number of subjects: 14
Study: 3792350

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride (combination therapy)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Diuretics (50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride)
Number of subjects: 27
Study: 30340474

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Schema Therapy (ST)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: DBT and ST
Number of subjects: 160
Study: 26829599

Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both MMF and EC-MPS
Number of subjects: 23
Study: 24072551

Group type: EXPERIMENTAL
Intervention: Glidescope laryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Induction of anaesthesia
Number of subjects: 100
Study: 24261229

Group type: EXPERIMENTAL
Intervention: BP < or = 140/90 mm Hg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: BP > or = 160/100 mm Hg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (apparently healthy individuals)
Number of subjects: 66
Study: 20533911

Group type: EXPERIMENTAL
Intervention: Anticipatory guidance intervention applied during pregnancy and at 6 and 12 months of age.
Number of subjects: 649

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 649
Study: 19249923

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl 0.5 microg/kg every 15 minutes (maximum 4 doses/hour)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PRN intravenous fentanyl 25-50 microg every 30 minutes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 16441618

Group type: EXPERIMENTAL
Intervention: Alginate gel Flaminal (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrocolloid gel Intrasite (control)
Number of subjects: 20
Study: 15531005

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 10886120

Group type: EXPERIMENTAL
Intervention: GR205171 25 mg i.v.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GR205171 25 mg i.v. + ondansetron 8 mg i.v.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hyoscine hydrobromide 0.6 mg orally (positive control)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9082268

Group type: EXPERIMENTAL
Intervention: Warm anesthetic solution (37 degrees C)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cold anesthetic solution (20 degrees C)
Number of subjects: 70
Study: 8452165

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 10 days
Number of subjects: 587

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg twice daily for 10 days
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 587

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Fleroxacin and Norfloxacin
Number of subjects: 587
Study: 3512783

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without bleomycin
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy with immunotherapy (BCG, levamisole, or both)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Initial full-dose therapy for patients aged 65 or older
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Initial dose reduction of 50% for patients aged 65 or older
Number of subjects: 307
Study: 29322313

Group type: EXPERIMENTAL
Intervention: Empty PEEK cages
Number of subjects: 45

Group type: COMPARATOR
Intervention: PEEK cages filled with β‐tricalcium phosphate
Number of subjects: 45
Study: 27716478

Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg once every 2 weeks
Number of subjects: 999

Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m2 followed by 250 mg/m2 weekly)
Number of subjects: 999
Study: 24781960

Group type: EXPERIMENTAL
Intervention: JADE + PEARL (n=312)
Number of subjects: 628

Group type: COMPARATOR
Intervention: JADE (n=316)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: JADE + PEARL
Number of subjects: 628

Group type: COMPARATOR
Intervention: JADE
Number of subjects: 628
Study: 21660669

Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) treatment for 30 min every morning during chemotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dim red light (DRL) treatment for 30 min every morning during chemotherapy
Number of subjects: 39
Study: 20351591

Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 22
Study: 18298356

Group type: EXPERIMENTAL
Intervention: High-intensity training group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-intensity training group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 65
Study: 16212074

Group type: EXPERIMENTAL
Intervention: DDD mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: VVIR mode
Number of subjects: 23
Study: 12379063

Group type: EXPERIMENTAL
Intervention: Rifampin and pyrazinamide daily for 2 months (n = 307)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Isoniazid daily for 6 months (n = 282)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Rifampin and pyrazinamide
Number of subjects: 589

Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 589
Study: 10355952

Group type: EXPERIMENTAL
Intervention: Sitting protocol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise protocol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Supine protocol
Number of subjects: 7
Study: 8576462

Group type: EXPERIMENTAL
Intervention: Maximum Intensity Projection (MIP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volume Rendering
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Surface Rendering
Number of subjects: 10
Study: 1850142

Group type: EXPERIMENTAL
Intervention: Flumazenil 200 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flumazenil 600 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6130073

Group type: EXPERIMENTAL
Intervention: 20 mg of buspirone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 15 mg of diazepam
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol (0.85 g/kg for men; 0.72 g/kg for women)
Number of subjects: 48
Study: 31420063

Group type: EXPERIMENTAL
Intervention: Featback (automated feedback on a short monitoring questionnaire weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Featback with weekly e‐mail or chat support from an expert patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly support from an expert patient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study: 28651769

Group type: EXPERIMENTAL
Intervention: Space Closure Group (SCG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Space Opening Group (SOG)
Number of subjects: 16
Study: 26215525

Group type: EXPERIMENTAL
Intervention: Facilitation using the VA HF COP
Number of subjects: 122

Group type: COMPARATOR
Intervention: No facilitation (control)
Number of subjects: 122
Study: 24573358

Group type: EXPERIMENTAL
Intervention: Transvaginal mesh
Number of subjects: 68

Group type: COMPARATOR
Intervention: Vaginal colposuspension
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 23080350

Group type: EXPERIMENTAL
Intervention: Subfascial injection of 30 mL of ropivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extrafascial injection of 30 mL of ropivacaine 0.5%
Number of subjects: 60
Study: 19374810

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 16950429

Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine (6 g/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15568141

Group type: EXPERIMENTAL
Intervention: Ethanol 0.73 g/kg, 1 h before isoniazid, followed by 0.11 g/kg ethanol orally every hour thereafter for 7 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no ethanol)
Number of subjects: 16
Study: 11406779

Group type: EXPERIMENTAL
Intervention: Normal cognitive score group (MMSE-K score >= 24)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Cognitive function test (MMSE-K)
Number of subjects: 449
Study: 9209670

Group type: EXPERIMENTAL
Intervention: Intrapleural combination of DDP (60 mg/m2) and CBDCA (270 mg/m2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single intravenous DDP treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of CBDCA alone
Number of subjects: 10
Study: 7525697

Group type: EXPERIMENTAL
Intervention: Essential type II mixed cryoglobulinemia
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Secondary type II mixed cryoglobulinemia
Number of subjects: 26
Study: 3453426

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31672681

Group type: EXPERIMENTAL
Intervention: Prophylactic mesh group (PMG) with onlay polypropylene mesh reinforcement
Number of subjects: 115

Group type: COMPARATOR
Intervention: Suture group (SG) with slowly absorbable running sutures
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Prophylactic mesh group (PMG)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Suture group (SG)
Number of subjects: 115
Study: 30293364

Group type: EXPERIMENTAL
Intervention: Combination treatment with narrow-spectrum intense pulsed light and fractional carbon dioxide laser
Number of subjects: 90

Group type: COMPARATOR
Intervention: Narrow-spectrum intense pulsed light alone (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination treatment group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 28634259

Group type: EXPERIMENTAL
Intervention: SUPR (online Support Programme) offered via email over 6-7 months, including a Practical Support Booklet and educational videos.
Number of subjects: 569

Group type: COMPARATOR
Intervention: Care as usual (hearing aid fitting without SUPR) in 34 practices.
Number of subjects: 569
Study: 26138472

Group type: EXPERIMENTAL
Intervention: AMG 811 (2 mg to 180 mg subcutaneously or 60 mg intravenously)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24169248

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA I-gel
Number of subjects: 90
Study: 21394052

Group type: EXPERIMENTAL
Intervention: 0.5‐mg ranibizumab
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 4‐mg triamcinolone
Number of subjects: 345

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 345
Study: 18329580

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT) (Helium Neon, 632.8 nm, 30 mW)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham low-level laser therapy (placebo)
Number of subjects: 52
Study: 14747424

Group type: EXPERIMENTAL
Intervention: 400 mg oral dose of imatinib (capsule)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg oral dose of imatinib (oral solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg i.v. infusion of imatinib
Number of subjects: 12
Study: 11113036

Group type: EXPERIMENTAL
Intervention: 200 microg clonidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9738622

Group type: EXPERIMENTAL
Intervention: Surgical Blood Order Equation (SBOE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maximal Surgical Blood Order Schedule (MSBOS)
Number of subjects: 60
Study: 8283896

Group type: EXPERIMENTAL
Intervention: Algorithm therapy based on on-site coagulation monitoring
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 66
Study: 2660970

Group type: EXPERIMENTAL
Intervention: Hyposensitization to house dust mite (D. pteronyssinus)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injections for 1 year
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-atopic asymptomatic controls
Number of subjects: 20
Study: 5343357

Group type: EXPERIMENTAL
Intervention: L-DOPA (high oral dosage)
Number of subjects: 0
Study: 31990328

Group type: EXPERIMENTAL
Intervention: Healthy Me programme (intervention)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Control (null group)
Number of subjects: 1120
Study: 31325524

Group type: EXPERIMENTAL
Intervention: Natural American Spirit (NAS) cigarettes
Number of subjects: 914

Group type: COMPARATOR
Intervention: Pall Mall cigarettes
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Company behind NAS
Number of subjects: 914
Study: 28987283

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 + 1 Hz rTMS
Number of subjects: 66
Study: 26958115

Group type: EXPERIMENTAL
Intervention: Brand A of Albendazole
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Brand B of Albendazole
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Brand C of Albendazole
Number of subjects: 715

Group type: COMPARATOR
Intervention: All brands of Albendazole
Number of subjects: 715
Study: 24051437

Group type: EXPERIMENTAL
Intervention: ERAP (cell‐permeable peptide inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (standard treatment)
Number of subjects: 0
Study: 21536689

Group type: EXPERIMENTAL
Intervention: Computer-assisted therapies
Number of subjects: 75

Group type: COMPARATOR
Intervention: Weaker comparison conditions (e.g., wait-list controls)
Number of subjects: 75
Study: 19192027

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16467234

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention with intensive behavior modification to reduce total fat intake to 20% of calories and increase vegetables/fruits to 5 servings/d and grains to at least 6 servings/d.
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Comparison group received diet-related education materials.
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention.
Number of subjects: 48835
Study: 15291859

Group type: EXPERIMENTAL
Intervention: Early and high-dose epirubicin (360 mg, 12 instillations)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Delayed and high-dose epirubicin (360 mg, 12 instillations)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Delayed low-dose epirubicin (180 mg, 30 mg once every 2 weeks, six times)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Early low-dose epirubicin (180 mg, three instillations before 7 days after TURBT)
Number of subjects: 69
Study: 11256987

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline, 0.5 mg three times daily for 2 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 400 microg twice daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 24
Study: 9048145

Group type: EXPERIMENTAL
Intervention: Enhanced methadone treatment
Number of subjects: 427

Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Powder cocaine use
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Crack cocaine use
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Continuous users of powder cocaine
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Continuous speedball users
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Crack users
Number of subjects: 427